Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 6:12:1358433.
doi: 10.3389/fpubh.2024.1358433. eCollection 2024.

Cervical cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with England and India based on the global burden of disease study 2019

Siyu Wu  1 , Jun Jiao  1 , Xiaoyu Yue  1 , Yaping Wang  1
Affiliations

Cervical cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with England and India based on the global burden of disease study 2019

Siyu Wu et al. Front Public Health. .

Abstract

Background: Cervical cancer is the fourth highest incidence of malignancy in the world and a common cause of cancer death in women. We assessed the trends of incidence and mortality and disability-adjusted life year (DALY) in China, England and India from 1990 to 2030.

Method: Data were obtained from the Global Burden of Disease (GBD) database. We collected the number and rate of incidence, death and DALY from 1990 to 2019 and calculated the estimated annual percentage change (EAPC). Further analysis was carried out by ages and years. We also collected attributable risk factors to cervical cancer. Finally, we utilized the Bayesian Age-Period-Cohort (BAPC) model to forecast trends in the rate of age-standardized incidence (ASIR) and age-standardized death (ASDR) the for the next decade.

Result: Globally, the incidence of cervical cancer cases increased from 335,641.56 in 1990 to 565,540.89 in 2019. In 2019, the ASIR and ASDR of cervical cancer were higher than those of India but lower than those of England. Furthermore, unsafe sex and smoking emerge as prominent risk factors for cervical cancer. Over the next decade, ASIR and ASDR are expected to decline in China and England, while India's ASIR is still on an upward trend and ASDR is on a downward trend.

Conclusion: The epidemiological data of cervical cancer in these three countries reflects the influence of different stages of development and healthcare systems. Trends over the next decade suggest that China and India still face a huge burden of cervical cancer. When England has made significant progress, China and India need to take more measures to improve the prevention and control of cervical cancer.

Keywords: China; England; India; cervical cancer; disease burden; incidence; mortality; projection.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Time trends of age-standardized incidence (A), mortality (B), and DALY (C) rates of cervical cancer in China, England and India. DALY, disability-adjusted life-years. k, thousand.
Figure 2
Figure 2
The number and rate of age-standardized incidences (A,D), deaths (B,E), and DALYs (C,F) of cervical cancer in China, England and India in 2019 by age.
Figure 3
Figure 3
Proportion of DALYs (A–C) and ASDR (D–F) attributable to all risk factors, unsafe sex and smoking, for China, England and India from 1990 to 2019. ASDR, age-standardized death rate.
Figure 4
Figure 4
The change trends of the ASIR and ASDR from 1990 to 2030 in China (A,B), England (C,D), and India (E,F). ASIR, age-standardized incidence rate.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2020) 71:209–49. doi: 10.3322/caac.21660 - DOI - PubMed
    1. Wright AA, Howitt BE, Myers AP, Dahlberg SE, Palescandolo E, Van Hummelen P, et al. . Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer. (2013) 119:3776–83. doi: 10.1002/cncr.28288, PMID: - DOI - PMC - PubMed
    1. Rahangdale L, Mungo C, O'Connor S, Chibwesha CJ, Brewer NT. Human papillomavirus vaccination and cervical cancer risk. BMJ. (2022) 379:e070115. doi: 10.1136/bmj-2022-070115 - DOI - PubMed
    1. Das M. WHO launches strategy to accelerate elimination of cervical cancer. Lancet Oncol. (2021) 22:20–1. doi: 10.1016/S1470-2045(20)30729-4 - DOI - PubMed
    1. Perkins RB, Wentzensen N, Guido RS, Schiffman M. Cervical Cancer screening: a review. JAMA. (2023) 330:547–58. doi: 10.1001/jama.2023.13174 - DOI - PubMed

Publication types